CTO-PCI Technology for Heart Health in Egypt

By Melike Belenli Gümüş

October 24, 2024

The article from the Egypt Healthcare Authority (EHA) discusses the successful implementation and benefits of using CTO-PCI (Chronic Total Occlusion Percutaneous Coronary Intervention) technology to treat chronic coronary artery occlusion in Egypt. Here are some key points to consider:

  • Success of Procedures: The EHA reported the successful treatment of three elderly patients (all over 60 years old) using CTO-PCI technology with micro-catheters and specialised wires at the International Medical Complex in Luxor. The procedures achieved a 100% success rate.
  • Cost and Universal Health Coverage: The cost of CTO-PCI procedures outside the universal health coverage system exceeds 500,000 Egyptian pounds. However, under the universal health insurance system, patients contribute no more than 400 EGP.
  • Medical Team and Expertise: The procedures were conducted by a highly skilled team of medical consultants, including top professors, cardiologists, and specialised nursing and technical staff. Key team members included Dr. Tarek Rashid, Head of the Scientific Committee for Cardiology, and Dr. Zein El-Abidin Abdel-Latif, Head of the Cardiology and Catheterization Department.
  • Commitment to Innovation: The EHA emphasised its commitment to innovation and continuous development, adopting the latest global medical advances and introducing cutting-edge technologies across all medical specialties, particularly in cardiology.
  • Patient Benefits: The patients treated were suffering from angina and severe pain due to coronary artery occlusion. The use of CTO-PCI technology significantly improved their quality of life.
  • Healthcare Model: The EHA aims to provide a modern healthcare model in Egypt by ensuring access to the latest global medical advancements and maintaining a team of expert consultants.

This initiative reflects the Authority‘s dedication to providing innovative medical technologies and achieving high-quality care for patients under the universal health insurance system.

Reference url

Recent Posts

lenacapavir HIV prevention
      

Lenacapavir HIV Prevention: Approval and Access Strategy Updates

🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!

#SyenzaNews #globalhealth #healthcareInnovation

Africa health partnership
      

Strengthening Africa Health Partnership

🌍 Can collaboration redefine Africa’s health landscape?

A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.

Look into the details of this transformative partnership and its implications for the future of healthcare in the region!

#SyenzaNews #globalhealth #HealthcareInnovation

breast cancer Africa
    

Urgent Call for Enhanced Breast Cancer Africa Control Measures

🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?

A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.

Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.

#SyenzaNews #globalhealth #oncology #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.